Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 4/20 | 0.54 |
| ▸ | HTR2B | P41595 | 3/20 | 0.54 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086647 | 0.95 | KMT2A (0.61) | KMT2AMEN1PKMHTR2CHTR2B | |
| SCHEMBL12448366 | 0.94 | KMT2A (0.60) | KMT2AMEN1PKMHTR2CHTR2B | |
| SCHEMBL31378679 | 0.89 | KMT2A (0.60) | KMT2AMEN1PKMKCNJ1CYP1A2 | |
| SCHEMBL1667288 | 0.89 | KMT2A (0.60) | KMT2AMEN1PKMKCNJ1CYP1A2 | |
| SCHEMBL1929880 | 0.89 | LTA4H (0.57) | KMT2AMEN1HTR2CHTR2BDRD4 | |
| SCHEMBL4042588 | 0.88 | KMT2A (0.59) | KMT2AMEN1PKMKCNJ1CYP1A2 | |
| SCHEMBL5476571 | 0.88 | LTA4H (0.56) | KMT2AMEN1HTR2CHTR2BDRD4 | |
| SCHEMBL4192478 | 0.88 | LTA4H (0.56) | KMT2AMEN1HTR2CHTR2BDRD4 | |
| SCHEMBL3214392 | 0.87 | NPC1 (0.55) | KMT2AMEN1PKMSYKCYP1A2 | |
| SCHEMBL5469381 | 0.86 | HTR2C (0.52) | KMT2AHTR2CHTR2BKCNJ1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651416-B1 | COMPOUNDS USEFUL FOR TREATING AIDS | ABIVAX (FR) | 2018-05-09 | — | — | EP | disclosed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | disclosed |
| EP-2651416-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | Splicos (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080953-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2012-06-21 | — | — | WO | disclosed |
| EP-2465502-A1 | Compounds useful for treating AIDS | Société Splicos (FR) | 2012-06-20 | — | — | EP | disclosed |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-1218360-B1 | TRIAZINE KINASE INHIBITORS | AMGEN INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1390354-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | Amgen Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003057220-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2003-07-17 | — | — | WO | disclosed |
| EP-1309551-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2003-05-14 | — | — | EP | disclosed |
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | GENENTECH, INC. AND HOECHST AKTIENGESELLSCHAFT | 2003-02-06 | — | — | US | disclosed |
| WO-2002083653-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6387895-B1 | BONE DISORDERS; CARDIOVASCULAR DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| WO-2002014273-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-21 | — | — | WO | disclosed |
| US-6207663-B1 | AS INHIBITORS OF BONE RESORPTION, TUMOR GROWTH, TUMOR METASTASIS, OR INFLAMMATION, OR FOR THE TREATMENT OR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS, NEPHROPATHIES OR RETINOPATHIES | HOECHST ATKIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| US-6011045-A | Vitronectin receptor antagonists, their preparation and their use | HOECHST AKTIENGESELLSCHAFT | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR3, CBR1, CCR10 | KMT2A 3215/4885MEN1 3379/4885PKM 4460/4885 |
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | HTR2C, HTR3C, HTR5A | KMT2A 3134/4885MEN1 4375/4885PKM 4484/4885 |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | KMT2A 2658/4885MEN1 2511/4885PKM 523/4885 |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | KMT2A 772/4885MEN1 291/4885PKM 3325/4885 |
| US-20030027807-A1 | Vitronectin receptor antagonists, their preparation and their use | ADGRF1, ADGRE5, BSG | KMT2A 4534/4885MEN1 642/4885PKM 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.